1Earls JP, Bluemke DA. New MR imaging contrast agents. Magn-Reson-Imaging-Clin-N-Am, 1999, 7:255.
2Hahn PF, Saini S. Liver-specific MR imaging contrast agents. Radiol Clin North Am, 1998, 36:287.
3Leander P. Liver-specific contrast media for MRI and CT experimental studies. Acta Radiol Suppl, 1995, 3961.
4Yu X, Song SK, Chen J,et al. High-resolution MRI characterization of human thrombus using a novel fibrin-targeted paramagnetic nanoparticle contrast agent. Magn-Reson-Med, 2000, 44:867.
5Lanza GM, Yu X, Winter PM, et al. Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: implications for rational therapy of restenosis. Cireulation, 2002, 106:2842.
6Frank H, Weissleder R, Papisov M. Presentation and quantification of acute myocardial infarct using antibody-boued MR contrast medium. Z-Kardiol, 1995, 84:311.
7Reimer P, Bader A, Weissleder R. Preclinical assessment of hepatocyte-targeted MR contrast agents in stable human liver cell cultures. J-Magn-Reson-Imagiag, 1998, 8:687.
8Small WC, Nelson RC, Sherbourne GM, et al. Enhancement effects of a hepatocyte receptor-specific MR contrast agent in an animal model. J-Magn-Reson-Imaging, 1994, 4:325.
9Tatsushi S, Soji O, Masakazu U, et al. Magnetic resonance imaging of esophageal squamous cell carcinoma using magnetite particles coated with anti-epidermal growth factor receptor antibody. Int J Cancer, 1998, 626.
10Anderson SA, Fader RK, West]in WF, et al. Magnetic resonance con-trast enhancement of neovasculature with alpha (v) beta (3)-targetednanoparticles. Magn-Reson-Med, 2000, 44:433.
8Sosnovik DE,Nahrendorf M,Weissleder R.Magnetic nanoparticles for MR imaging:agents,techniques and cardiovascular applications.Basic Res Cardiol.2008;103(2):122-130.
